Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults

Schwarz, Tino F.; Horacek, Thomas; Knuf, Markus; Damman, Hanns-Gerd; Roman, François; Dramé, Mamadou; Gillard, Paul; Jilg, Wolfgang

doi:10.1016/j.vaccine.2009.01.040

Cited by 111 publications

(83 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This suggests the existence of some level of immunological priming of the population for the A/H1N1/2009 strain, despite the fact that it is antigenically and genetically distinct from recently circulating influenza virus A H1N1 strains (13,15). This is supported by the observation that, prior to vaccination, 32% to 45% of our Belgian study participants and 48% to 78% of adults in another study in the United States (29) had baseline detectable antibodies against the A/H1N1/2009 strain, while only 0.7% to 3% of subjects in H5N1 vaccine studies had baseline detectable antibodies against H5N1 strains (3,22,33,36). As subjects with a medical history suggestive of influenza in the 6 months prior to the study were excluded, preexisting antibodies are unlikely to be due to prior infection with A/H1N1/2009, although there may have been some asymptomatic cases.…”

Section: Discussionsupporting

confidence: 70%

Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials

Roman

Clement

Dewé

et al. 2011

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 70%

Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials

Roman

Clement

Dewé

et al. 2011

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

“…By enhancing vaccine immunogenicity, adjuvants may allow for dose-sparing in vaccines, driving comparable immune responses with smaller amounts of antigen. Dose sparing is a critical consideration when urgent large-scale vaccination is needed and vaccine production is limited (5)(6)(7). Similarly, use of adjuvants may reduce the number of vaccinations required for any given vaccine, easing compliance issues and, in much of the world, logistical challenges.…”

mentioning

confidence: 99%

Schistosoma mansoni Soluble Egg Antigens Enhance Listeria monocytogenes Vector HIV-1 Vaccine Induction of Cytotoxic T Cells

Bui

Shollenberger

Paterson

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Vaccines are an important public health measure for prevention and treatment of diseases. In addition to the vaccine immunogen, many vaccines incorporate adjuvants to stimulate the recipient's immune system and enhance vaccine-specific responses. While vaccine development has advanced from attenuated organism to recombinant protein or use of plasmid DNA, the development of new adjuvants that safely increase immune responses has not kept pace. Previous studies have shown that the complex mixture of molecules that comprise saline soluble egg antigens (SEA) from Schistosoma mansoni eggs functions to promote CD4 ؉ T helper 2 (Th2) responses. Therefore, we hypothesized that coadministration of SEA with a Listeria vector HIV-1 Gag (Lm-Gag) vaccine would suppress host cytotoxic T lymphocyte (CTL) and T helper 1 (Th1) responses to HIV-1 Gag epitopes. Surprisingly, instead of driving HIV-1 Gag-specific responses toward Th2 type, we found that coadministration of SEA with LmGag vaccine significantly increased the frequency of gamma interferon (IFN-␥)-producing Gag-specific Th1 and CTL responses over that seen in mice administered Lm-Gag only. Analysis of the functionality and durability of vaccine responses suggested that SEA not only enlarged different memory T cell compartments but induced functional and long-lasting vaccine-specific responses as well. These results suggest there are components in SEA that can synergize with potent inducers of strong and durable Th1-type responses such as those to Listeria. We hypothesize that SEA contains moieties that, if defined, can be used to expand type 1 proinflammatory responses for use in vaccines.

show abstract

“…HA-based vaccines have been shown to elicit higher titers of neutralizing antibodies to prevent influenza virus infection in tested animals (15)(16)(17)(18), as well as human clinical trials (19)(20)(21)(22). The HA1 antigenic domain of HA has been demonstrated to induce an immune response equal to that of the full-size protein (23).…”

Section: Discussionmentioning

confidence: 99%

A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responses

Qiu

et al. 2013

Biosci Trends

View full text Add to dashboard Cite

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults

Cited by 111 publications

References 23 publications

Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials

Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials

Schistosoma mansoni Soluble Egg Antigens Enhance Listeria monocytogenes Vector HIV-1 Vaccine Induction of Cytotoxic T Cells

A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responses

Contact Info

Product

Resources

About